Mode
Text Size
Log in / Sign up

Local therapy and intrathecal chemotherapy may manage CNS progression in EGFR-mutant NSCLC patientsCombined Treatments May Help Manage Brain Metastases in Lung Cancer

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that local therapy combined with intrathecal chemotherapy may manage CNS progression in EGFR-mutant NSCLC.

This publication consists of a case report and review of the literature regarding a patient with lung adenocarcinoma and non-small cell lung cancer (NSCLC) harboring an EGFR mutation. The patient presented with brain parenchymal metastasis and leptomeningeal metastasis while undergoing treatment.

The authors synthesize findings suggesting that the combination of ventriculoperitoneal shunting, intrathecal chemotherapy via an Ommaya reservoir, surgical resection of a brain metastatic lesion, and EGFR-tyrosine kinase inhibitor therapy effectively controlled the patient's condition. The report highlights these interventions as potential methods to improve quality of life and prolong survival in patients experiencing CNS progression.

A primary limitation is that the evidence is based on a single case report, which means the results are not generalizable to the broader population. Clinical application should be interpreted with caution due to the small sample size. The findings suggest that some EGFR-mutant NSCLC patients may still experience CNS progression despite receiving EGFR-tyrosine kinase inhibitor therapy.

How this fits prior evidence

This case report addresses a gap in management for patients experiencing CNS progression during EGFR-tyrosine kinase inhibitor (TKI) therapy. While previous reports have explored specific resistance mechanisms, such as transformation to pulmonary giant cell carcinoma or the use of ivonescimab for TKI-resistant lung adenocarcinoma with pericardial effusion, this report focuses on local and intrathecal interventions for brain and leptomeningeal involvement.

This report looks at a single patient with a specific type of lung cancer called EGFR-mutant non-small cell lung cancer. The patient had the cancer spread to the brain and the lining of the brain. Even though they were already taking a targeted drug, the cancer continued to spread in these areas.

The patient received a combination of treatments including surgery to remove a brain lesion, a special delivery system for chemotherapy, and a procedure to drain fluid. These steps helped control the cancer in the brain area. The report suggests that combining local treatments with systemic drugs might improve quality of life and help patients live longer.

Because this information comes from only one person, it is not enough to know if this approach works for everyone. It shows a possible way to treat advanced cases where standard medicine alone may not stop the cancer from moving into the brain. You should talk with your doctor about how these specific treatments might apply to a personal diagnosis.

What this means for you:
A combined treatment approach showed promise for one patient, but more research is needed to confirm its effectiveness.

Common questions

What specific type of lung cancer was treated?

The treatment was used for a patient with EGFR-mutant non-small cell lung cancer (NSCLC). This specific type of cancer had spread to the brain and the lining of the brain. The case shows that even when patients are on targeted drugs, they may still need additional local treatments to manage the spread.

What were the components of the treatment plan?

The patient received a combination of several methods: surgery to remove a brain lesion, ventriculoperitoneal shunting, and intrathecal chemotherapy delivered via an Ommaya reservoir. These were used alongside an EGFR-tyrosine kinase inhibitor therapy to manage the cancer's progression in the central nervous system.

Can this treatment be used for all lung cancer patients?

Because this was a single case report, these results cannot be applied to everyone. The study only observed one patient. While it suggests that combining local therapies with targeted drugs might improve outcomes for some people, you must consult your doctor to see if any of these options are appropriate for a specific case.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedJul 2026
View Original Abstract ↓
Brain metastasis (BM) represents a severe and common complication of advanced lung cancer, which is clinically categorized into brain parenchymal metastasis (BPM) and leptomeningeal metastasis (LM), with LM being the predominant subtype of meningeal involvement. In clinical practice, the concurrent occurrence of both parenchymal brain and leptomeningeal metastases in a single patient remains rare. Here, we report a case of an epidermal growth factor receptor (EGFR)-mutant NSCLC patient with simultaneous BPM and LM, along with a review of current research progress on the treatment of BM. The patient had previously undergone surgery and targeted therapy, and subsequently developed bone metastases, LM and BPM. After receiving ventriculoperitoneal shunting, intrathecal chemotherapy via an Ommaya reservoir, and resection of the brain metastatic lesion, the patient’s condition was effectively controlled. This case suggests that some EGFR-mutant NSCLC patients may still experience CNS progression during EGFR-tyrosine kinase inhibitor (TKI) therapy. Moreover, local therapy (surgery) combined with intrathecal chemotherapy may improve quality of life and prolong survival, thus representing a feasible treatment option.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.